Show simple item record

AuthorAl AdAwi R.M.
AuthorJassim Z.
AuthorElgaily D.
AuthorAbdelaziz H.
AuthorSree B.
AuthorMohamed Ibrahim M.I.
Available date2020-04-01T06:54:48Z
Publication Date2019
Publication NameScientific Reports
ResourceScopus
ISSN20452322
URIhttp://dx.doi.org/10.1038/s41598-019-43052-6
URIhttp://hdl.handle.net/10576/13638
AbstractThe effectiveness of dapagliflozin in the management of type-2 diabetes mellitus (T2-DM) is an essential issue for establishing a basis for prescribing dapagliflozin. This study aimed to assess the effectiveness of dapagliflozin in combination with other hypoglycemic agents (OHAs) in reducing glycated hemoglobin (HbA1c) and fasting blood glucose (FBG) at 3, 6, 9 and 12 months. This retrospective observational study included all patients who visited the endocrine clinics at Hamad Medical Corporation (HMC) and were treated with dapagliflozin. Demographics and laboratory data were obtained retrospectively from computerized patient medical profiles (eMR-viewer). The main outcome measures were the differences in HbA1c and FBG from baseline at different months. Eighty-one Qatari patients were found to have received dapagliflozin during the study period; 72% of them (n = 58) were males, with a mean age of 57.0 ± 9.0 years and a mean baseline HbA1c of 9.0 ± 1.4%. Administration of dapagliflozin as an add-on therapy was found to decrease HbA1c significantly by 0.8 percentage point after 6 months (P = 0.006) and by 1.5 percentage point after 12 months (P = 0.062). FBG was significantly reduced at 6 months and 9 months (P = 0.001 and P = 0.03, respectively). Dapagliflozin effectively reduced the HbA1c level and FBG when used in combination with other OHAs or insulin within 6 to 12 months. © 2019, The Author(s).
SponsorEthical approval. This study was approved by the Institutional Review Board at the Medical Research Center of Hamad Medical Corporation. The authors would like to thank the Hamad Medical Corporation for proving the research funding. This work was supported by the Medical Research Center of Hamad Medical Corporation [grant number 15292/15].
Languageen
PublisherNature Publishing Group
SubjectSodium-Glucose Transport Proteins
Sodium-Glucose Transporter 2
Glucose co-transporter
TitleAssessment of Dapagliflozin Effectiveness as Add-on Therapy for the Treatment of Type 2 Diabetes Mellitus in a Qatari Population
TypeArticle
Issue Number1
Volume Number9


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record